Invasive fungal disease (IFD) is a life-threatening event in immunocompromised patients, and there is an urgent need for reliable screening methods facilitating rapid and broad detection of pathogenic fungi. We have established a two-reaction real-time PCR assay permitting highly sensitive detection of more than 80 fungal pathogens, covering a large spectrum of moulds, yeasts and Zygomycetes. To assess the clinical potential of the assay, more than 600 consecutive specimens from 125 pediatric patients carrying a high risk of IFD were analyzed. An excellent correlation between PCR positivity and the presence of proven, probable or possible fungal infection according to the European Organization for Research and Treatment of Cancer criteria was demonstrated, as revealed by the sensitivity of the assay of 96% (95% CI: 82-99%). The negative predictive value of the panfungal PCR assay presented was 98% (95% CI: 90-100%), while the specificity and the positive predictive value were 77% (95% CI: 66-85%) and 62% (95% CI: 47-75%), respectively. The results indicate that molecular screening of patients during febrile neutropenic episodes by the assay presented could help prevent unnecessary toxicity resulting from empirical antifungal treatment in individuals who may not be at risk of imminent fungal disease. Our observations raise the possibility that rapid species identification may be required to increase the positive predictive value for impending fungus-related disease.
Introduction
Invasive fungal disease (IFD) is a leading cause of morbidity and mortality in severely immunocompromised individuals, including particularly patients with hematological malignancies and bone-marrow transplant recipients. The vast majority of IFD events are still caused by Candida and Aspergillus species; however, changes in the epidemiology have occurred over the past decades. [1] [2] [3] [4] [5] Recent studies from North American and European centers indicate an increasing incidence of previously uncommon fungal genera, such as Cryptococcus, Trichosporon, Malassezia, 6, 7 Fusarium, 8, 9 Scedosporium, Pseudallescheria, 10, 11 and, very importantly, different members of the class Zygomycetes, such as Rhizopus and Mucor.
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Timely detection of the fungal pathogens is a prerequisite for successful therapy and the clinical outcome in patients with IFD. In view of the changing epidemiology and the increasing variety of fungal genera and species observed in immunosuppressed patients, there is a growing demand for broad-spectrum diagnostic tests. Many of the published technical approaches based on real-time PCR methods are rapid and sensitive, but their detection spectrum is mostly restricted to a variety of Candida 13, 14 or Aspergillus species, 15, 16 or representatives of both genera. [17] [18] [19] [20] [21] Diagnostic assays permitting the detection of a wide range of fungal pathogens including fungal species of both common and emerging fungal genera are therefore required. To address the urgent clinical need, we have developed a panfungal real-time PCR assay permitting the detection of at least 80 pathogenic fungal species (European patent application 06817468.9). Herein, we describe the technical features of the assay, and present a combined prospective and retrospective study in severely immunocompromised pediatric patients carrying a high risk of invasive fungal infection, with the aim to assess the potential clinical benefit of molecular screening by a highly sensitive broadspectrum fungus detection test.
Materials and methods

Fungal strains, bacterial and viral isolates
Fungal strains for PCR testing (Table 1) were obtained from different institutions, including the American Type Culture Collection (ATCC, Rockville, USA), the German Collection of Micro-organisms (DSM, Braunschweig, Germany) and the Institute of Hygiene and Medical Microbiology of the University of Vienna (IHMM, Austria).
Clinical materials
Clinical specimens from consecutive patients were obtained after informed consent, and were prospectively collected as specified below. In total, 618 peripheral blood specimens from 125 pediatric hemato-oncological patients undergoing intensive chemotherapy (n ¼ 65) or allogeneic stem cell transplantation (n ¼ 60) were analyzed during 150 episodes of febrile neutropenia. Whenever possible, specimens were collected at first onset of fever, within 48 h thereafter, and at subsequent time points in the course of the febrile episode, upon availability. On average, four peripheral blood samples were investigated during each episode (range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . In selected instances, depending on availability, additional types of specimens derived from primarily sterile sites of suspected infection were collected and subjected to molecular analysis. These included cerebrospinal fluid (n ¼ 11) and lung biopsies (n ¼ 2) in patients with suspected central nervous system or pulmonary involvement, respectively, in order to correlate the data with the PCR findings in peripheral blood samples. The specimens used as training set for initial data assessment were provided by the Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands, and the specimens used as validation set were provided by the St Anna Children's Hospital of Vienna, Austria. Plasma or serum was usually collected from 3-ml samples of peripheral blood and all samples were stored at À80 1C until further processing. Peripheral blood specimens from healthy volunteer donors were used to test for cross-reactivity with human DNA (see below).
DNA extraction
The isolation and purification of fungal DNA were performed essentially as described earlier, with minor modifications. 17 All steps were performed in a laminar flow hood using one-way sterile utensils and sterile-filtered reagents. DNA isolation from bacteria and virus specimens for the assessment of crossreactivity was performed using the QIAamp DNA Mini Kit (QIAGEN GmbH, Hilden, Germany).
Real-time PCR
The panfungal PCR detection assay included two separate reactions, I and II, each covering different subsets of fungal pathogens, as outlined in Table 1 . Both PCR reactions targeted a highly conserved region of the 28S ribosomal RNA multicopy gene. The PCR reactions were set up in a total volume of 25 ml containing Gene Expression Mastermix 2 Â with uracil N-glycosylase (UNG) (Applied Biosystems, Foster City, CA, USA), primers and probes as listed in Table 2 , and molecular biology grade water (Eppendorf, Hamburg, Germany). Locked nucleic acid nucleotides were included in the primer and probe sequences to obtain high specificity despite short length. 22 The amplification was performed on a TaqMan 7900 instrument 
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Assessment of cross-reactivity with bacterial, viral and human DNA
Potential cross-reactivity of the panfungal detection assay with non-fungal micro-organisms was analyzed by testing a total of 20 different bacterial and viral pathogens. Multiple isolates of DNA derived from different human peripheral blood specimens were also tested for cross-reactivity in this setting (not shown).
Controls
A number of positive and negative controls were included in the panfungal real-time assay as described earlier. 23 In view of the lack of fungus-grade reagents guaranteed to be free of contamination by fungal particles or DNA, highly stringent measures to control and exclude contamination were performed to minimize the risk of false-positive results of the molecular screening assay.
Specificity of the real-time PCR assays
Differences in the detection efficiency of individual pathogens determined by testing defined concentrations of fungal species were in the range of ±1 cycle threshold (CT) value. The only exceptions were the fungal species Geotrichum candidum, Malassezia furfur, Mucor hiemalis, Candida lipolytica and Acremonium strictum, which revealed higher CT values (in the range of þ 3), apparently due to mismatches within regions targeted by the primers.
Sensitivity of the real-time PCR assays
To determine the detection limit of the real-time PCR assays, serial logarithmic dilutions across a 6-log range (1 fg to 100 pg) of genomic DNA derived from A. fumigatus and C. albicans, as representatives for moulds and yeasts, respectively, were analyzed. Standard curves were generated on the basis of the amplification profile.
Definition of PCR positivity and DNAemia
All clinical specimens were analyzed in duplicates. A PCR result was regarded as positive when both CT values were either p36.5 in reaction I or p37.5 in reaction II, reflecting the respective y-intercept values. In the event of single positive values of the duplicate measurement, the CT had to be p34.5 in reaction I and p35.5 in reaction II to be regarded as PCRpositive. For the diagnosis of fungal DNAemia, a minimum of two PCR-positive peripheral blood specimens derived at subsequent time points during close follow-up investigation were required. In the rare instances in which only one specimen from a febrile neutropenic episode was available, a single PCRpositive result was regarded as indicative of DNAemia.
Statistical analysis
Results of panfungal PCR analysis in relation to the presence or absence of possible, probable or proven IFD by the European Organization for Research and Treatment of Cancer (EORTC) criteria were used for the calculation of sensitivity and specificity, and the corresponding negative predictive values (NPV) and positive predictive values (PPV) of the assay. Individual values and the corresponding 95% confidence intervals (CIs) were calculated using the method of Wilson. 24 
Results
Design and principle of the panfungal PCR assay
The universal primers and probes for the two-reaction panfungal PCR assay were judiciously selected on the basis of their homology to highly conserved sequences within the 28S gene based on the sequence alignment of more than 80 fungal species (Tables 1 and 2 ). The primers display a degenerated code required for efficient amplification of fungal species that differ from others at single-nucleotide positions. In order to obtain optimal binding affinity, locked nucleic acid modifications of individual nucleotides were included in the hybridization probes and the reverse primers (Table 2 ). Owing to the exploitation of a multi-copy target gene, the detection limit of the panfungal PCR assay is in the range of 1 fg fungal DNA per reaction, which corresponds to a fraction of a single fungal genome equivalent.
Detection spectrum and specificity of the panfungal PCR assay
To document the detection spectrum of the two-reaction panfungal PCR assay, multiple strains/isolates of 61 different Primer and probe sequences included in the panfungal PCR assay. Reaction I covers moulds and reaction II primarily yeasts and Zygomycetes. Nucleotides within brackets carry LNA modifications. a The sequence accession numbers are based on A. fumigatus (U28460) and C. albicans (Z48339).
Panfungal real-time PCR assay for diagnosis of IFD C Landlinger et al fungal species (Table 1) were analyzed experimentally in repeated tests. However, based on extensive sequence alignments, the panfungal real-time PCR assay presented can be expected to cover more than 80 different fungal species (Table 1) . Reaction I was designed to permit detection and quantitative assessment of a variety of moulds (nX29), whereas reaction II targets a broad range of yeasts and Zygomycetes (nX58). The assay therefore permits the detection of coinfections by different fungal genera, which may not be uncommon in immunocompromised individuals. Cross-reactivity between reactions I and II was observed at a high concentration of fungal template DNA (X100 fg/reaction). However, the amplification efficiencies for moulds and yeasts/ Zygomycetes by the appropriate detection systems were about 3 logs higher, thereby permitting clear identification of the dominant class of fungal pathogen present. At the concentrations of fungal pathogens observed in most clinical specimens of immunocompromised individuals, the cross-reactivity was not relevant. The lack of cross-reactivity of the panfungal PCR assay with non-fungal pathogens or human genomic DNA was assessed by extensive testing of various bacterial and viral DNA isolates, and peripheral blood specimens of healthy volunteer donors, as specified in the Materials and methods section.
Analysis of clinical specimens by the panfungal PCR assay in relation to the EORTC criteria for IFD
The analyses of clinical specimens were performed in a doubleblinded manner to prevent any bias or influence on treatment decisions. First, a training set of 165 peripheral blood specimens derived from 43 pediatric patients with a high risk of IFD was analyzed by the panfungal PCR assay in a retrospective study in order to generate preliminary data on the potential clinical utility of the test system. The patients were generally in febrile neutropenia at the time of sample collection. In total, 71 specimens (43%) tested PCR-positive, 34 in reaction I, 15 in reaction II and 22 in both reactions, with CT values clearly beyond the level of potential cross-reactivity. The results of molecular testing were evaluated in relation to the criteria proposed by the EORTC, 25 and indicated that all patients with proven or probable IFD, and all but one case with possible IFD tested repeatedly PCR-positive, as specified in Table 3 . In three instances, both PCR reactions revealed positive results indicative of mixed infections (Table 3) .
Five patients received empirical antifungal therapy on the basis of clinical suspicion of fungal infection, which did not meet the EORTC definition of possible IFD (generally by the absence of an appropriate clinical criterion), and three of these patients were also positive by the panfungal PCR assay (Table 3) . However, consecutive PCR-positive results were also obtained in 6 of 27 instances, with no clinical indication of IFD in patients who were on antifungal prophylaxis only or did not receive any kind of antimycotic treatment (Table 3) . Hence, analysis of the training data set indicated a good correlation between repeated positivity of the panfungal PCR assay and the presence of proven, probable and possible IFD by the EORTC criteria, by revealing a sensitivity of the panfungal screening assay of 91% (95% CI: 62-98%), and an NPV of 95% (95% CI: 78-99%). Although it might be more appropriate to calculate the NPV of the panfungal PCR assay on the basis of proven and probable IFD only, we have also included patients classified as having a possible IFD in the calculation in order to obtain a value applicable to any level of IFD according to the EORTC criteria.
A problem in the specificity of panfungal PCR-positive results became particularly apparent in the presence of single positive tests, and in follow-up samples collected at extended time intervals (43 days) during febrile neutropenia. Based on the presence of positive PCR tests, according to the definition indicated in Materials and methods, the specificity of the assay was 78% (95% CI: 59-89%), and the PPV 63% (95% CI: 39-82%).
On the basis of the insights gained from analysis of the training set, a larger cohort of immunocompromised pediatric patients was investigated, with a focus on febrile neutropenic episodes and the requirement of consecutive samples collected at short time intervals (1-2 days). A total of 453 consecutive peripheral blood samples derived from 107 febrile neutropenic episodes in 82 pediatric patients with hemato-oncological malignancies (n ¼ 22) or hematopoietic stem cell transplant recipients (n ¼ 60) were analyzed. Similar to the first cohort tested, 212 specimens (47%) tested PCR-positive, 122 in reaction I (58%) and 45 in reaction II (21%). Forty-five samples (21%) were positive in both reactions, with differences in CT values clearly beyond the level of potential cross-reactivity, hence indicating a mixed infection. Overall, 51 of 107 febrile neutropenic episodes investigated revealed repeatedly positive Table 3 Analysis of clinical specimens: training set (Table 4 ). There was no statistically significant difference between allogeneic stem cell transplant recipients and non-transplant patients with regard to the occurrence of panfungal PCR positivity in peripheral blood during the neutropenic febrile episodes (50 vs 39%; two-sided P-value ¼ 0.29). PCR positivity was observed in all cases of IFD according to EORTC criteria (n ¼ 16), revealing a sensitivity of 100% (95% CI: 81-100%) and an NPV of 100% (95% CI: 90-100%).
All patients with proven, probable and possible IFD (n ¼ 16) tested repeatedly PCR positive, as specified in Table 4 . In five instances, both PCR reactions revealed positive results indicative of mixed infections with different fungal genera (Table 4) . In all 16 patients with IFD, positive PCR results were already detected in the specimens collected at first onset of fever within a febrile neutropenic episode.
In 48 instances, patients with febrile neutropenia received empirical antifungal treatment despite the lack of findings supporting the presence of IFD according to the EORTC criteria. Only 25 of these patients revealed evidence of IFD by panfungal PCR analysis (Table 4 ). In patients with no clinical indication of IFD, including individuals receiving antifungal prophylaxis only and individuals without any antimycotic treatment, repeatedly positive test results by the panfungal PCR assay were obtained in 10 out of 43 (23%) febrile neutropenic episodes (Table 4 ). The observations made in the validation patient cohort therefore reflected a specificity of the assay at the level of 77% (95% CI: 62-87%) and a PPV of 62% (9% CI: 42-76%).
Evaluation of the molecular assay in both patient cohorts combined revealed a sensitivity of 96% (95%CI: 82-99%) and a specificity of 77% (95%CI: 66-85%), corresponding to an NPV of 98% (95%CI: 90-100%) and a PPV of 62% (95%CI: 47-75%).
Discussion
Over the previous years, a small number of prospective studies have assessed the clinical utility of different PCR assays in hematopoietic stem cell transplantation recipients and/or patients with hematological malignancies. 18, 19, [26] [27] [28] The reported sensitivity and the NPV were moderate to high. The specificity was generally lower, but could be significantly improved by establishing the requirement of two consecutive positive PCR results as a diagnostic criterion. 29, 30 However, the diagnostic reliability of PCR assays in peripheral blood and serum specimens has been described to be rather limited. 31, 32 The panfungal real-time PCR assay presented was specifically adapted to highly sensitive detection of fungal pathogens in peripheral blood or serum. In the current combined prospective and retrospective study, more than 600 clinical specimens from 150 febrile neutropenic episodes in pediatric patients with high risk of IFD were investigated by the panfungal real-time PCR assay described. Evaluation of the molecular screening data, which had been generated in a double-blinded manner, revealed an excellent correlation with the EORTC definitions of proven, probable and possible invasive fungal infection. The sensitivity and NPV in the validation cohort of patients were in the range of 100%, indicating that molecular screening might be instrumental in preventing unnecessary treatment. The possible benefit of this notion is underlined by the observation that nearly half of the febrile neutropenic episodes studied were treated empirically by antifungal agents, despite the lack of evidence for IFD according to the EORTC criteria. The absence of fungemia determined by the panfungal PCR assay in about 50% of these episodes suggests that a high proportion of patients were probably over-treated.
The limited specificity and PPV of the panfungal PCR assay reflect the fact that even in severely immunocompromised patient populations, repeated or persistent detection of fungemia by sensitive, broad-spectrum PCR methods may not generally indicate an imminent risk of severe fungal disease. This observation might be interpreted as frequent occurrence of false positivity, most likely attributable to contamination. However, owing to the processing of test materials in a sterile environment, the use of internally tested reagents and the number of controls included in each assay, it may be an explanation for some, but very likely not all, seemingly false-positive findings. Of the PCR-positive patients who received either no antifungal treatment at all or prophylaxis only (n ¼ 16), fungal disease was diagnosed during the subsequent clinically documented febrile episode early thereafter in two patients, raising the possibility that subclinical fungemia was present at the time of the febrile episode investigated. In two additional patients, fungus-positive cultures from urine and throat were obtained at the time of PCR positivity, indicating the presence of fungal infection or colonization. However, based on the current EORTC criteria, these patients could not be classified as having IFD at any level Panfungal real-time PCR assay for diagnosis of IFD C Landlinger et al of probability. In five patients, treatment with semi-synthetic penicillins was documented during the febrile episodes investigated. These substances were reported to yield falsepositive results in serological fungus detection tests, and it cannot be excluded that the occurrence of cross-reactivity with molecular detection assays might have accounted for false positivity of the panfungal PCR assay. In seven patients, no findings possibly explaining the PCR-positive results could be identified. The limited correlation between positive panfungal PCR results and imminent fungal disease may also reflect the relatively common occurrence of fungemia caused by environmental fungi, such as Alternaria or Cladosporium species, which might display low pathogenicity even in immunosuppressed individuals. 33, 34 To assess this notion, clinical implementation of methods facilitating reliable identification of these species at an adequate level of sensitivity would be required. A number of methods for rapid typing of fungal pathogens have been published, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] and the development of novel and expectedly more potent methods is currently underway, including also approaches based on the exploitation of nano-technological devices, as currently pursued in our laboratory. Rapid and sensitive techniques for the identification of putatively non-or low-pathogenic environmental fungal species that may cause clinically silent fungemia could improve the interpretation of results obtained by broad-spectrum PCR screening methods. This might contribute to an increased specificity of molecular monitoring with regard to more reliable assessment of the expected clinical relevance of fungemia. Hence, routine clinical implementation of methods for rapid identification of fungal species could provide a basis for better assessment of the need for treatment and for selection of the most appropriate antimycotic agent, if therapy appears to be required.
The lack of a gold standard for the assessment of IFD presents a problem in the interpretation of new diagnostic approaches. The criteria of proven, probable and possible IFD proposed by the EORTC are widely accepted, but the diagnostic tests permitting the assessment of proven or even probable infection, such as histological examination of targeted biopsies, imageguided analyses (for example, computer tomography), blood cultures and serological tests, are not available in many high-risk patients, also including a large proportion of patients in the present study. The reliability of serological testing by galactomannan in pediatric patients is, however, questionable. It has been reported that galactomannan tests frequently yield falsepositive results in the pediatric population. This observation was mainly attributable to dietary factors (for example, various brands of milk formulas 46, 47 or soybean protein 48 ) and, in the general population, to the use of semi-synthetic penicillins. 49, 50 Routine employment of a broader set of diagnostic methods, including image-guided analysis, blood culture and serological testing, in carefully designed clinical studies would be required to assess and finally exploit the full diagnostic potential of the panfungal PCR screening assay presented. The design of appropriate large-scale clinical studies is currently underway.
